GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Numeral Ltd (XMAU:GOLI.N0000) » Definitions » ROE %

Numeral (XMAU:GOLI.N0000) ROE % : Negative Equity% (As of Aug. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Numeral ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Numeral's annualized net income for the quarter that ended in Aug. 2024 was $0.48 Mil. Numeral's average Total Stockholders Equity over the quarter that ended in Aug. 2024 was $-0.09 Mil. Therefore, Numeral's annualized ROE % for the quarter that ended in Aug. 2024 was Negative Equity%.

The historical rank and industry rank for Numeral's ROE % or its related term are showing as below:

XMAU:GOLI.N0000' s ROE % Range Over the Past 10 Years
Min: -206.9   Med: -2.07   Max: 9.21
Current: Negative Equity

During the past 10 years, Numeral's highest ROE % was 9.21%. The lowest was -206.90%. And the median was -2.07%.

XMAU:GOLI.N0000's ROE % is ranked better than
99.9% of 964 companies
in the Drug Manufacturers industry
Industry Median: 4.275 vs XMAU:GOLI.N0000: Negative Equity

Numeral ROE % Historical Data

The historical data trend for Numeral's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Numeral ROE % Chart

Numeral Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Feb18 Feb19 Feb20 Feb21 Feb22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.21 -0.21 -206.90 - -

Numeral Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 Nov19 Feb20 Aug20 Nov20 Feb21 Aug21 Nov21 Feb22 Aug22 Nov22 May23 Aug23 Nov23 May24 Aug24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - Negative Equity Negative Equity

Competitive Comparison of Numeral's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Numeral's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Numeral's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Numeral's ROE % distribution charts can be found below:

* The bar in red indicates where Numeral's ROE % falls into.



Numeral ROE % Calculation

Numeral's annualized ROE % for the fiscal year that ended in Feb. 2022 is calculated as

ROE %=Net Income (A: Feb. 2022 )/( (Total Stockholders Equity (A: Feb. 2021 )+Total Stockholders Equity (A: Feb. 2022 ))/ count )
=-0.063/( (-0.266+-0.329)/ 2 )
=-0.063/-0.2975
=N/A %

Numeral's annualized ROE % for the quarter that ended in Aug. 2024 is calculated as

ROE %=Net Income (Q: Aug. 2024 )/( (Total Stockholders Equity (Q: May. 2024 )+Total Stockholders Equity (Q: Aug. 2024 ))/ count )
=0.484/( (-0.145+-0.025)/ 2 )
=0.484/-0.085
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Aug. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Numeral  (XMAU:GOLI.N0000) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Aug. 2024 )
=Net Income/Total Stockholders Equity
=0.484/-0.085
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.484 / 0.716)*(0.716 / 0.14)*(0.14 / -0.085)
=Net Margin %*Asset Turnover*Equity Multiplier
=67.6 %*5.1143*N/A
=ROA %*Equity Multiplier
=345.73 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Aug. 2024 )
=Net Income/Total Stockholders Equity
=0.484/-0.085
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (0.484 / 0.484) * (0.484 / 0.484) * (0.484 / 0.716) * (0.716 / 0.14) * (0.14 / -0.085)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1 * 67.6 % * 5.1143 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Aug. 2024) net income data. The Revenue data used here is four times the quarterly (Aug. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Numeral ROE % Related Terms

Thank you for viewing the detailed overview of Numeral's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Numeral Business Description

Traded in Other Exchanges
Address
142, Mosque Road, Midlands, MUS
Numeral Ltd is a multi-faceted healthcare company offering a comprehensive all-inclusive product range that addresses market needs from pharmaceutical, generic, nutraceutical, medical consumables through to high end sophisticated hospital equipment.

Numeral Headlines

No Headlines